TVTX SEC Form 4 filings

Travere Therapeutics, Inc. Latest Insider Trading Activity

Over the past 42 days, Travere Therapeutics, Inc. (TVTX) has had 43 total open-market insider transactions represented in the displayed records. The latest displayed record by transaction date reports 3 sales by Dube Eric M (Travere Therapeutics, Inc. CHIEF EXECUTIVE OFFICER) totaling 243,735 shares at a weighted-average price of $53.82 per share, with the latest transaction dated October 15, 2026. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.

Insider Trading For TVTX Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).

▲ Insider buy ▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
Ticker Filing Date Transaction Date Company Insider Title Transaction Trade Count Shares Avg. Price Total Value Position Size Change SEC Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-10-19 2026-10-15 Travere Therapeutics, Inc. Dube Eric M CHIEF EXECUTIVE OFFICER Sell 3 243,735 $53.82 $13,116,670.65 36.02% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-17 Travere Therapeutics, Inc. Heerma Peter EVP, CHIEF COMMERCIAL OFFICER Sell 1 8,282 $65.07 $538,917.19 6.61% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-17 Travere Therapeutics, Inc. Dube Eric M CHIEF EXECUTIVE OFFICER Sell 8 400,000 $63.48 $25,390,729.21 48.03% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-16 Travere Therapeutics, Inc. Heerma Peter EVP, CHIEF COMMERCIAL OFFICER Sell 6 274,907 $63.00 $17,318,912.77 70.13% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-16 Travere Therapeutics, Inc. Rote William E. Chief Research Officer Sell 6 209,048 $62.83 $13,135,397.45 68.04% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-15 Travere Therapeutics, Inc. Inrig Jula EVP, Head of R&D & CMO Sell 4 44,674 $62.34 $2,785,020.69 30.77% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-15 Travere Therapeutics, Inc. Cline Christopher R. CHIEF FINANCIAL OFFICER Sell 4 50,508 $62.34 $3,148,543.99 36.60% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-15 Travere Therapeutics, Inc. Reed Elizabeth E Chief Legal Officer and GC Sell 4 37,500 $62.34 $2,337,695.09 26.24% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-17 2026-09-15 Travere Therapeutics, Inc. Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER Sell 3 5,375 $62.33 $335,004.59 11.26% View Filing
10b5-1: Scheduled Form 4 Transaction TVTX 2026-09-11 2026-09-10 Travere Therapeutics, Inc. Meckler Jeffrey A Director Sell 4 20,000 $67.31 $1,346,106.29 4.71% View Filing

Pricing

Free Trial

10 trading days
$0

Explore every Premium feature before you pay.

  • Full platform access
  • 10 trading days
  • No credit card required
  • 20 years of alert history
  • Live alert directory updates
Start your free trial

Standard Monthly

Scheduled
$19.99 / month

Scheduled alerts with complete trade context.

  • Email and Telegram delivery
  • Alert intervals from every sixty minutes to once daily
  • Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
  • Highlighted cluster transactions and SEC filing links
  • Access to the alert directory hourly refreshes
Choose Standard Monthly

Premium Monthly

Recommended
$29.99 / month

Fastest alerts with ticker-level control.

  • Everything in Standard
  • Instant delivery detection-to-outbound time averages 3.00 seconds
  • Alert intervals starting from one minute
  • Real time alert directory updates
Choose Premium Monthly
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.